Abstract
Background
Hyperalgesia is a heightened pain response to a noxious stimulus and is a hallmark of many common neuropathic and chronic pain conditions. In a double‐blind placebo‐controlled drug‐crossover trial the effects of concomitant and delayed minocycline treatment on the initiation and resolution of muscle hyperalgesia were tested.
Methods
An initial cohort (n=10) received repeated injections (5 µg: days 0, 2 and 4) of nerve growth factor (NGF) in the flexor carpi ulnaris muscle of the forearm and pressure pain thresholds were collected at day 0 (control), day 7 (peak) and day 14 (recovery). A second cohort (n=18) underwent an identical procedure, however, half received a placebo between days 0‐7 before switching to minocycline from days 7‐14 (P1/M2), while the remaining subjects received minocycline (day 0: 200mg then 100mg b.i.d. for 7 days) before switching to placebo (M1/P2).
Results
The initial cohort exhibited a diffuse muscular pain hypersensitivity with a decrease in pressure pain thresholds at day 7 before a partial return to normalcy at day 14. The P1/M2 treatment group exhibited an identical peak in hypersensitivity at day 7, however, after switching to minocycline in week 2 showed a significant reduction in muscle hyperalgesia compared to the initial cohort at day 14. The M1/P2 treatment group had significantly less (~50%) hyperalgesia at day 7 compared to the other groups.
Conclusions
This study indicates that the administration of minocycline can reduce experimentally induced muscle pain regardless of the time of administration.
from Wiley: European Journal of Pain: Table of Contents https://ift.tt/2U7tlL9
via IFTTT
No comments:
Post a Comment